Last reviewed · How we verify
Tacholiquine
Tacholiquine is a Small molecule drug developed by bene-Arzneimittel GmbH. It is currently FDA-approved.
Tacholiquine is a medication that has been studied in clinical trials for its effectiveness in treating chronic bronchitis and chronic obstructive pulmonary disease. It has been tested in a double-blind, placebo-controlled, randomized crossover trial to evaluate its mucolytic effectiveness in chronic bronchitis.
At a glance
| Generic name | Tacholiquine |
|---|---|
| Sponsor | bene-Arzneimittel GmbH |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tacholiquine CI brief — competitive landscape report
- Tacholiquine updates RSS · CI watch RSS
- bene-Arzneimittel GmbH portfolio CI
Frequently asked questions about Tacholiquine
What is Tacholiquine?
Who makes Tacholiquine?
What development phase is Tacholiquine in?
Related
- Manufacturer: bene-Arzneimittel GmbH — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing